Abstract:Abstract Liquid biopsy holds great promise in noninvasive diagnosis of cancers through detecting minute amounts of cell-free DNA released from cancer cells in non-solid biologic tissue such as peripheral blood. A critical bottleneck in developing liquid biopsy methods is the limited accuracy of current next-generation sequencing technology (NGS), evidenced by its high error rate (0.1%-1%, as of 2018). Through mathematical modeling of NGS errors, we have recently published a method to computationally suppress the current NGS error rate to between 10−5 and 10−4, two orders of magnitude lower than general reports. However, this error rate is a product of both PCR errors and instrument (i.e., sequencer) errors, and it is currently unknown how to separate these error sources. In this work, we developed a novel computational algorithm to precisely measure the errors caused by sequencers. By using 12 publicly available datasets from 10 sequencing centers (in America, Europe, and Asia), we discovered highly reproducible patterns of sequencer errors, including: 1) the overall sequencer error rate is 10−5; 2) at the flow-cell level, error rates are elevated in the bottom surface; 3) almost all flow cells have a small fraction of random tiles with a dramatically elevated error rate; 4) the elevated error rates appear to be enriched in some reaction cycles; 5) removal of these reaction cycles yields 5-fold lower error rates at some genomic loci, so that A>C, A>T, and C>G error types have error rates close to 10−6; and 6) sequencer errors have a pattern markedly distinct from PCR errors. We have implemented the above observations into a general-purpose algorithm, termed CleanDeepSeq2, to computationally suppress sequencer errors and to also effectively monitor sequencer anomalies. CleanDeepSeq2 was engineered for efficiency so that a dataset with ultra-deep sequencing (1,000,000X depth) can be processed in 1.5N minutes on a single CPU core, where N is the number of target regions. Similarly, WES (100X) and WGS (~30X) datasets can be processed in under 1 CPU hour in order to monitor instrument performance. Overall, we have developed a computational method that for the first time enabled precise measurement of sequencer errors. Our study revealed novel insights on sequencer errors that can lead to improved instrumentation, NGS chemistry, and ultimately higher DNA sequencing fidelity. In addition, our developed software can efficiently suppress sequencer errors in addition to previously discovered error sources. Citation Format: Eric Davis, Rain Sun, Ying Shao, Yanling Liu, Heather L. Mulder, Stephen V. Rice, John Easton, Jinghui Zhang, Xiaotu Ma. Uncovering instrument errors in next-generation sequencing by CleanDeepSeq2 [abstract]. In: Proceedings of the AACR Special Conference on Advances in Liquid Biopsies; Jan 13-16, 2020; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(11_Suppl):Abstract nr A57.

Optimizing Accuracy and Efficiency in Analyzing Non-UMI Liquid Biopsy Datasets Using the Sentieon ctDNA Pipeline

Processing UMI Datasets at High Accuracy and Efficiency with the Sentieon ctDNA Analysis Pipeline

Comprehensive detection of ctDNA variants at 0.1% allelic frequency using a broad targeted NGS panel for liquid biopsy research.

Ultra-deep sequencing with unique molecular identifier(UMI) for detection of ctDNA by fragment profiling using machine learning.

High efficiency error suppression for accurate detection of low-frequency variants

Evaluating Bioinformatics Processing of Somatic Variant Detection in cfDNA Using Targeted Sequencing with UMIs

Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology

CancerScreen: A Novel Ultrasensitive Liquid Biopsy for Early-Stage Cancer Detection by Ctdna Duplex Sequencing and Tissue of Origin Identification with Supervised Machine Learning.

Benchmarking UMI-aware and standard variant callers for low frequency ctDNA variant detection

Abstract P19: Comprehensive Benchmark of Somatic Mutation Callers on Cell-Free DNA Next-Generation Sequencing Data in Cancer Liquid Biopsy

Single-stranded linear amplification library preparation method for highly sensitive and low input amount ctDNA detection.

Application of Data Science in Circulating Tumor DNA Detection: A Promising Avenue Towards Liquid Biopsy.

The Early Diagnosis in Lung Cancer by the Detection of Circulating Tumor DNA

Abstract 151: an Improved Computational Pipeline for Tumor Somatic Alterations Detection

Computational performance and accuracy of Sentieon DNASeq variant calling workflow

An Ultra-Deep Next Generation Sequencing Method for Cfdna Detection in Nsclc Patients.

Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control

A unique molecular identifier-based and clonal hematopoiesis-aware approach for accurate mutation calling in cell-free DNA assays.

Towards an Accurate and Robust Analysis Pipeline for Somatic Mutation Calling

Integrating Cycled Enzymatic DNA Amplification and Surface-Enhanced Raman Scattering for Sensitive Detection of Circulating Tumor DNA

Abstract A57: Uncovering Instrument Errors in Next-Generation Sequencing by CleanDeepSeq2